Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above 200-Day Moving Average – Should You Sell?

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $3.94 and traded as high as $5.81. Cumberland Pharmaceuticals shares last traded at $5.67, with a volume of 28,570 shares changing hands.

Wall Street Analyst Weigh In

CPIX has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen lowered shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Trading Up 3.5%

The stock has a market cap of $84.94 million, a PE ratio of -11.57 and a beta of 0.09. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.79 and a current ratio of 0.95. The company’s 50-day moving average price is $4.51 and its 200 day moving average price is $3.94.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). Cumberland Pharmaceuticals had a negative net margin of 17.60% and a negative return on equity of 12.01%. The firm had revenue of $9.13 million for the quarter, compared to analyst estimates of $8.50 million.

Institutional Trading of Cumberland Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in Cumberland Pharmaceuticals in the 2nd quarter valued at approximately $34,000. Arrowstreet Capital Limited Partnership acquired a new stake in Cumberland Pharmaceuticals in the 1st quarter valued at approximately $66,000. Two Sigma Investments LP increased its holdings in Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,326 shares during the last quarter. Marshall Wace LLP acquired a new stake in Cumberland Pharmaceuticals in the 4th quarter valued at approximately $192,000. Finally, Geode Capital Management LLC increased its holdings in Cumberland Pharmaceuticals by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after purchasing an additional 5,653 shares during the last quarter. Institutional investors and hedge funds own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.